SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 25, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $10.25 per share. The gross proceeds to Veracyte from this offering,
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 24, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares are being offered by Veracyte .
Revenue up 24% to $22.8 Million Compared to Second Quarter 2017 Increasing Revenue and Narrowing Cash Burn Guidance for Full-year 2018 Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 23, 2018-- Veracyte, Inc.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will report its second quarter 2018 financial results after the close of market on Monday, July 23, 2018 . Following the announcement, Veracyte will host a conference call and webcast
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 2, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie Anderson , chairman and chief executive officer, will speak at the 2018 MedCity CONVERGE conference in a session entitled, “Early Diagnosis Through Predictive Biomarkers,
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 25, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it has been awarded a 2018 Top Workplaces honor by the Bay Area News Group . This marks the fifth consecutive year that Veracyte has received this prestigious award, which is based
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 30, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, will present at the William Blair 38 th Annual Growth Stock Conference on Wednesday, June 13, 2018 at 12:40 p.m.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 23, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that clinical validation data published for the first time today – in JAMA Surgery – demonstrate that the next-generation Afirma Genomic Sequencing Classifier (GSC) identifies at least one third
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 19, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that early user-experience data from three independent studies demonstrate that the next-generation Afirma Genomic Sequencing Classifier (GSC) significantly increases the number of patients who can
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 17, 2018-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it has launched an Early Access Program to begin making the Envisia Genomic Classifier available to patients being evaluated for interstitial lung diseases (ILD), including idiopathic
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
